CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 40 enrolled
Drug / intervention
Group 1 Tranexamic Acid +1 moredrug
Likely dose
Group 2 Platelet rich plasma 16mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02650856
NCT02650856Phase 3Completed

Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial

Universidad Autonoma de Nuevo Leon·interventional·Posted Jan 8, 2016·Updated May 26, 2021

In Brief

A Phase 3 clinical trial evaluating Group 1 Tranexamic Acid and Group 2 Platelet rich plasma for Osteoarthritis. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The investigators will include patients who will be schedule for total knee arthroplasty with a diagnosis of osteoarthritis. The patients will be divided in two groups. In both groups a verbal and clear detailed information will be given on the intraoperative approach. The first group will receive topical tranexamic acid and the second group topical platelet rich plasma; both in the surgical site. Both groups will be assessed before and after the intervention with laboratory results (hemoglobin, hematocrit levels) and drainage drain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesMexico
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 8, 2016
Enrollment StartSep 1, 2015
Primary CompletionMar 9, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.5 years ago

Interventions

Group 1 Tranexamic Aciddrug

2 gr of tranexamic acid will be applied on the surgical site.

Group 2 Platelet rich plasmabiological

16ml of platelet rich plasma will be applied of the surgical site